Yonesaka Kimio

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (1)： cancer

Research theme for competitive and other funds (3)：

2021 - 2025 Exploring mechanism underlying resistance to kras inhibitor
2017 - 2019 頭頸部癌におけるセツキシマブ治療の耐性機序の解明
2014 - 2016 HER2陽性乳癌、胃癌におけるheregulinによる抗HER2薬の効果予測

Papers (91)：

Kimio Yonesaka, Hidetoshi Hayashi, Atsushi Nakamura, Yuki Sato, Koichi Azuma, Shinya Sakata, Motoko Tachihara, Satoshi Ikeda, Toshihide Yokoyama, Kentaro Ito, et al. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial. Clinical lung cancer. 2023
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, et al. Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2023. 20. 2. 290-290
Kana Fujimoto, Satomi Watanabe, Yuto Yasuda, Emi Date, Yasuhiro Kawabata, Hiroaki Kanemura, Takayuki Takahama, Kimio Yonesaka, Norishige Iizuka, Ken-Ichi Takahashi, et al. Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report. Thoracic cancer. 2023. 14. 2. 214-217
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, et al. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus : official journal of the Japan Esophageal Society. 2022. 20. 2. 281-289
Kohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, Yusuke Makutani, Hisato Kawakami, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Tsutomu Iwasa, Hidetoshi Hayashi, et al. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis. Lung cancer (Amsterdam, Netherlands). 2022. 174. 71-82

ｍore...

MISC (99)：

金村宙昌, 竹原俊幸, 小野寺勇太, 寺村岳士, 鈴木慎一郎, 坂井和子, 西尾和人, 中川和彦, 林秀敏, 米阪仁雄. PTPRRを介したEGFR活性化に起因するKRASG12C阻害薬耐性の克服(Combating acquired resistance to KRAS inhibitors in NSCLC by targeting PTPRR-mediated activation of EGFR signaling). 日本癌学会総会記事. 2023. 82回. 422-422
米阪仁雄, 稲垣千昌, 稲垣千昌, 高濱隆幸, 高濱隆幸, 白石直樹, 磯本晃佑, 金村宙昌, 鈴木慎一郎, 谷崎潤子, et al. Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling. 日本癌学会学術総会抄録集(Web). 2023. 82nd
高濱隆幸, 高濱隆幸, 米阪仁雄, 米阪仁雄, 谷崎潤子, 田中薫, 鈴木慎一郎, 金村宙昌, 磯本晃佑, 白石直樹, et al. 肺癌に対する遺伝子パネル検査の実際と出口戦略の検討. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Kazuko Sakai, Maki Kobayashi, Ryoto Yoshimoto, et al. EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402. ANNALS OF ONCOLOGY. 2021. 32. S296-S296
米阪仁雄, 林秀敏, 鈴木慎一郎, 加藤了資, 武田真幸, 中川和彦, 岩間映二, 岡本勇, 安宅信二, 西尾和人. HER3リガンド・ヘレグリン陽性肺癌のEGFRチロシンキナーゼ(EGFR-TKI)への治療抵抗性について. 肺癌(Web). 2020. 60. 2

ｍore...

Professional career (1)：

博士 (近畿大学)

Awards (8)：

2018 - 日本肺癌学会篠井河合賞
2018 - 近畿大学医学会賞
2018 - 第22回日本がん分子標的治療学会優秀演題賞
2012 - AACR 2012 Clinical Scholar award, AACR annual meeting
2011 - Best eight proffered abstract, EORTC-NCI-ASCO meeting, Belgium

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page